.jpg)
【News_EN】
new order | old order
.jpg)

RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)

RevolKa Ltd. Secures 210 million JPY (US$1.4 million) Series A Extension Funding to Advance Therapeutic Programs

RevolKa expanding research projects with Daiichi Sankyo

RevolKa announces the closing of ¥250 million series A extension funding to accelerate Drug-Discovery programs

RevolKa Started joint research of a drug discovery program for rare diseases

RevolKa launched a drug discovery program for rare diseases

RevolKa completed the contract research with SEKISUI CHEMICAL CO., LTD

RevolKa Signed Master Service Agreement with Daiichi Sankyo

La Jolla Institute for Immunology and RevolKa started a Research Collaboration
LATEST ARTICLE
ARCHIVE
- 2025/07 (3)
- 2025/06 (3)
- 2025/05 (5)
- 2025/03 (3)
- 2025/02 (4)
- 2024/11 (1)
- 2024/10 (1)
- 2024/08 (4)
- 2024/07 (4)
- 2024/05 (2)
- 2024/04 (2)
- 2024/03 (1)
CATEGORY
View allTAG